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Zusammenfassung
Hintergrund: Einige Patienten, die eine radikale Prostatektomie
(RPx) wegen eines organbegrenzten Tumors erhielten, weisen
trotz eines negativen Absetzungsrandes ein PSA(Prostata-spezi-
fisches Antigen)-Rezidiv auf. Ziel der Studie war es, diese Grup-
pe von Patienten näher zu untersuchen, die anderenfalls als ge-
heilt angesehen worden wäre. Patienten und Methoden: Seit
der Einführung von PSA-Analysen bei der Nachsorge unserer
Patienten nach RPx, wurden von 1988 bis 1997 475 pelvine
Lymphknotenausräumungen mit nachfolgender RPx durchge-
führt. 227 davon wurden als pT2 beurteilt, 34 (15%) wiesen
einen positiven Absetzungsrand auf, und 4 weitere wurden
wegen ungenügender Nachsorge von der Analyse ausgeschlos-
sen. Von den übrigen 189 Patienten (Studien-Kohorte) entwi-
ckelten 19 (10%) ein biochemisches Rezidiv, definiert als mini-
mal 2 aufeinander folgende PSA-Messungen ≥ 0,1 ng/ml. Nur
bei einem Fall wurde ein G3-Tumor nachgewiesen. Die mediane
Nachsorgezeit erreichte 19,1 Monate. Ergebnisse: Die Kaplan-
Meier-Analyse für biochemische Progression zeigte, dass nach
jeweils einem, 2 und 5 Jahren 95% (Konfidenz-Intervall (CI)
91–99%), 91% (CI 86–96%), und 77% (CI 55–89%) der Patienten
progressionsfrei waren. Dies bedeutet, dass ungefähr ein Vier-
tel der Tumoren im Stadium pT2 trotz negativer Absetzungsrän-
der progressiv werden. Diese 19 Patienten wurden in 4 Grup-
pen unterteilt: 1: Durch Biopsie nachgewiesenes lokales Rezidiv
(n = 2); 2: Vermutliches Lokalrezidiv definiert als langsam stei-
gender PSA-Wert ≤ 2 ng/ml, aber negative Biopsien (n = 12); 3:
Durch Röntgendiagnose bewiesene Fernmetastasierung (n = 1);
4: vermutliche Fernmetastasierung definiert als schnell steigen-
der PSA-Wert > 9 ng/ml ohne direkten radiologischen Beweis (n
= 4). Alle Patienten der Gruppen 3 + 4 waren negativ im präope-
rativen Knochenszintigramm, und 4/5 wiesen präoperative PSA-
Werte < 10 ng/ml auf. Insgesamt konnten bei 7 Patienten mit
nachgewiesener Metastasierung oder Lokalrezidiv positive
Biopsien erhalten werden. Schlussfolgerungen: Die histopatho-
logische Diagnose eines organbegrenzten Tumors (pT2) und
eine intensive Analyse von negativen Absetzungsrändern
schließt in 7% (14/189) der Fälle das Auftreten von Lokalrezidi-
ven nicht aus, und es finden sich Hinweise für eine primäre hä-
matogene Metastasierung des Prostatakarzinoms in zumindest
2% (4/189) der Fälle. 
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Summary 
Background: Some patients from our radical prostatectomy
(RPx) series with organ-confined (pT2) prostate cancer and ne-
gative surgical margins show a PSA (prostate specific antigen)
relapse. Aim of the study was to analyze this cohort of patients
that otherwise would have been considered to be cured. Pa-
tients and Methods: Since the introduction of PSA measure-
ment in the follow-up after RPx, 475 pelvic lymph node dissec-
tions with subsequent RPx were performed in our department
from 1988 to 1997. Of these, 227 were classified as pT2, 34
(15%) exhibited positive surgical margins, and 4 others were
excluded due to an inadequate follow-up. Of the remaining 189
patients (study cohort), 19 (10%) developed a biochemical pro-
gression, defined as a minimum of 2 consecutive PSA measure-
ments ≥ 0.1 ng/ml. Only in one of them a G3 tumor was present.
Median follow-up was 19.1 months. Results: The Kaplan-Meier
analysis of biochemical progression showed that after 1, 2 and
5 years, 95% (confidence interval (Cl) 91–99%), 91% (Cl 86–96%),
and 77% (Cl 55–89%) of the patients were free of progression,
respectively. This means that roughly one fourth of pT2 tumors
will become progressive despite negative surgical margins.
These 19 patients were subdivided into 4 groups: 1: biopsy-pro-
ven local recurrence (n = 2); 2: suspected local recurrence defi-
ned as slowly rising PSA ≤ 2 ng/ml, but negative biopsies (n =
12); 3: distant metastasis proven by radiologic imaging (n = 1);
4: suspected distant metastasis defined as rapidly rising PSA >
9 ng/ml without direct radiologic evidence (n = 4). Preoperative-
ly all patients from groups 3 + 4 had negative bone scans and
4/5 had preoperative PSA values < 10 ng/ml. In total 7 patients
with proven recurrence or with proven metastasis had positive
biopsies. Conclusion: A pathological diagnosis of organ-confi-
ned prostate cancer (pT2) and a meticulous analysis of negative
surgical margins do not exclude the occurrence of local relap-
ses in 7% (14/189), and there is evidence for suspect hematoge-
nic spread of PC cells in at least 2% (4/189) of patients. 
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It is generally accepted that PSA (prostate specific antigen) is
produced nearly exclusively by prostatic epithelial cells [1].
Because the curative intent of radical prostatectomy is to re-
move all prostatic tissue (normal, benign prostatic hyperpla-
sia, and adenocarcinoma), serum PSA should decline to unde-
tectable concentrations after radical surgery. With the excep-
tion of a few and mostly anecdotal reports of local recurrences
after radical prostatectomy with undetectable serum PSA con-
centrations [2], most men with disease recurring after surgery
either locally [3, 4] or as distant spread [5, 6] have detectable
serum PSA levels. 
Most large series evaluated PSA progression in the context of
tumors exhibiting capsular penetration (> pT3), with a posi-
tive surgical margin status bearing a negative impact on prog-
nosis [7, 8]. Overall, surgical margin status has been reported
to be of equivocal significance [9, 10], particularly in organ-
confined disease [11]. 
This article focuses on the use of serum PSA after anatomic
radical prostatectomy for pathologically localized prostate
cancer so as to investigate cancer progression in a group of
patients that normally would have been considered to be
cured. 
Patients and Methods 
From January 1, 1988 to December 31, 1997, 475 bilateral pelvic lymph
node dissections with subsequent retropubic radical prostatectomies were
performed at the Department of Urology, Erasmus University Hospital,
Rotterdam by or under the guidance of a certified urologic surgeon. The
date January 1988 was chosen as the initial date because this is when
serum PSA concentrations became available for routine clinical use at our
institution. Consequently, the minimum observation period for this cohort
of patients was 54 months. During this same interval, an additional 52 men
were found to have positive lymph nodes at frozen section and as a result
did not undergo radical prostatectomy. Patients were aged 43–75 years
with a median of 66 years. 
Preoperative tumor staging consisted of digital rectal examination, serum
PSA determination and radioisoptope bone scanning with confirmatory
imaging studies, if necessary. All tumors were histologically proven by
means of ultrasound-guided transrectal sixtant biopsies. In all patients, the
tumor was judged clinically to be radically resectable. 
The radical prostatectomy specimens were graded histologically according
to the Gleason system and categorized as being well (Gleason sums 2–4),
moderately (Gleason sums 5–7) or poorly (Gleason sums 8–10) differenti-
ated. The TNM system of 1992 was used for clinical and pathological stag-
ing. Frozen sections and subsequent paraffin-embedded sections of all
lymph nodes removed during the bilateral pelvic lymph node dissection
were examined. Immediately after resection, the pathologist investigated
the radical prostatectomy specimens by gross inspection, weighed them,
coated the entire external surface with India ink [12] and fixed the speci-
mens in 10% formalin for 18–24 hours. All paraffin fixed surgical margins
including the prostatic base, apex, urethra, bladder neck, capsule, peripro-
static soft tissue, seminal vesicles and multiple routine step sections of the
prostate, perpendicular to the long axis (apical-basal) were examined his-
tologically. Pathologic stage was determined as organ-confined (≤pT2),
capsular penetration (pT3a+b) or seminal vesicle involvement (pT3c).
The surgical margin status was regarded positive when the tumor extend-
ed at any given section to the inked surface. 
We prospectively entered clinical and pathological data in our follow-up
data base. Patients were evaluated quarterly for the first year, biannually
for the next year and annually thereafter if there was no evidence of can-
cer progression. We contact patients who do not comply with this sched-
ule by mail or by telephone. Digital rectal examination and PSA testing
was performed at each visit. PSA of ≥ 0.1 ng/ml at two consecutive mea-
surements was considered evidence of biochemical progression. Ra-
dioisoptope bone scanning with confirmatory imaging studies, if neces-
sary, were done in the event of a postoperative PSA elevation. Local re-
currence was established by transrectal ultrasound-guided biopsy of the
anastomotic region. Progression was defined as elevated postoperative
PSA, local recurrence or distant metastasis. 
The radical prostatectomy specimens were routinely fixed in 10%
buffered formalin, pH = 7.4, embedded in paraffin, freshly cut into 4 µm
sections and mounted on amino alkylsilane coated glass slides. Hema-
toxylin and eosin slides were reviewed by a specialized uro-pathologist.
The Gleason growth pattern was determined for all tumor sections in the
prostate and the tumor was staged according to the 1992 pathological
TNM system. Of all specimens 1–3 paraffin tissue blocks representative of
the whole tumor were selected. Selection was based on the presence of
the poorest grade in the radical prostatectomy specimens, assuming that
these growth patterns in the tumor would predict outcome. 
Results 
Of our patients 227 (48%) were classified as stage pT2 (organ-
confined) of whom 34 (15%) exhibited positive surgical mar-
gins (17 apically, 16 laterally, 1 both). 4 others were excluded
due to inadequate follow-up. Of the remaining 189 patients
(study cohort; 40% of total patient population; 83% of pT2
tumors), 19 (10%) developed a biochemical progression as a
first indication for cancer progression; in some cases a PSA-
relapse after reaching undetectable levels occurred within the





























Fig. 1. Prognostic implication of positive surgical margins. Kaplan-Meier
estimates on the probability of biochemical progression after curative ra-
dical prostatectomy in organ-confined disease (n = 189). Surg marg: surgi-






























   
   
   





















first year postoperatively. 7 patients (4%) had a well, 11 pa-
tients (5%) a moderately and only 1 patient (1%) a poorly dif-
ferentiated tumor. 
The Kaplan-Meier biochemical progression analysis showed
that after 1 year 95% (confidence interval 91–99%) were free
of progression. The same result applied after 2 years to 91%
(confidence interval 86–96%), and after 5 years to 77% (con-
fidence interval 55–89%) of the study group. This means that
overall one fourth of patients with organ-confined prostate
cancer will become progressive despite negative surgical mar-
gins at radical prostatectomy. Furthermore, we analyzed the
prognostic impact of the surgical margin status in the group of
organ-confined (pT2) prostate cancer. Figure 1 clearly demon-
strates that the probability of biochemical progression after
radical prostatectomy in pT2 disease is significantly associated
with presence or absence of a putative surgical eradication of
prostate cancer cells from the primary tumor site. 
Moreover, we subdivided the 19 progressive patients into 4
groups in accordance with the pattern of PSA-relapse over
time: 
1: biopsy-proven local recurrence (n = 2; 1% of study cohort),
2: suspected local recurrence, but negative biopsies (n = 12;
6% of study cohort), 
3: radiologic imaging proven distant metastasis (n = 1); 1% of
study cohort), 
4: suspected distant metastasis, but negative bone scans (n =
4; 2% of study cohort). 
Patients from groups 1 and 2 showed a slowly rising PSA ≤ 2
ng/ml, whereas patients from groups 3 and 4 presented with a
rapidly rising PSA > 9 ng/ml. All patients from the latter 
2 groups demonstrated negative bone scans preoperatively,
and 4/5 had preoperative PSA values < 10 ng/ml. Except for
one case who exhibited a micro-metastasis at definitive paraf-
fin section (frozen section negative), all pelvic lymph node dis-
sections revealed no lymphatic spread of prostate cancer. 7 of
the 19 progressive patients had positive biopsies or were high-
ly suspected for distant metastasis (4% of study cohort). 
Hence, a pathological diagnosis of organ-confined prostate
cancer and a meticulous analysis of negative surgical margins
does not exclude the occurrence of a local relapse in 7%
(14/189), and there is evidence for a suspect primary hemato-
genic spread of prostate cancer in at least 2% (4/189) of pa-
tients. 
Discussion 
Radical prostatectomy is an effective therapy for prostate can-
cer, especially when the tumor is organ-confined at final
pathological analysis [4, 7, 8]. However, it is apparent that
5–23% of those patients will experience recurrences even
when lesions are confined pathologically to the prostate and
surgical margins are reported to be negative. Thus, the natural
history of prostate cancer can be variable following definitive
therapy. Although a 10- to 15-year follow-up is necessary to
definitively quantify clinical progression rates, the availability
of serum PSA as a marker of persistent or recurrent disease
has telescoped the time to tumor progression, thus allowing
for interim evaluation of disease status in patients followed
for shorter intervals like in our study. 
An increase in serum PSA after the patient had achieved fe-
male levels may precede clinical evidence of local recurrence
or distant metastasis by several months or years, although the
clinical relevance of such postoperative elevations is not en-
tirely clear [9]. Nonetheless, PSA is presently the most sensi-
tive and specific marker available to monitor patients after
radical prostatectomy. The half-life of serum PSA is 3.15 days
[1]. While the technology is still evolving and there remains
some controversy [1], an undetectable serum PSA concentra-
tion is less than 0.1 ng/ml. This would predict that even a
serum PSA concentration of 50 ng/ml should become unde-
tectable 30 days after surgical removal of the prostate. Several
studies have investigated the significance of measurable serum
PSA within the first year after surgery. Stein et al. [3] reported
that 50% of 14 men who had detectable serum PSA concen-
trations within one year after prostatectomy subsequently de-
veloped either local recurrence or distant disease. Lange et al.
[13] described 100% (16/16) progression, and in the Catalona
series [9] a 51% (17/33) progression rate became obvious for
similar groups of patients. The largest cohort [10] demonstrat-
ed a 60% (23/38) progression rate for men who had detectable
serum PSA within the first postoperative year. Both the 5- and
the 10-year actuarial progression-free probabilities for those
patients with PSA recurrences within the first year are signifi-
cantly lower than those for men whose disease recurred after
the first year [10]. 
Because the majority of patients in our series experienced de-
tectable PSA concentrations within the initial postoperative
year, there is ample evidence that the biochemical progression
analyzed in this study will eventually translate into clinical re-
currences even in this group of patients with organ-confined
prostate cancer with negative surgical margins that otherwise
would have been considered to be cured. Indeed, only the in-
troduction of PSA in the follow-up after radical prostatectomy
has made it possible to detect this new subgroup of prostate
cancer patients. 
Failure of radical prostatectomy for apparent pathologically
organ-confined tumor is not easily understood. PSA values
that remain persistently elevated despite organ-confined dis-
ease may represent subclinical hematogeneous metastases or
incomplete resection of the primary tumor with pathological
tissue sampling error. However, PSA elevations after initial
return to undetectable levels like in our series are even more
difficult to explain. Again, an erroneous pathological classifi-
cation involving either cancer penetrating the prostate capsule
(pT3) and/or an anatomically incorrect dissection plane (unre-
vealed positive surgical margins), leaving minute amounts of
prostatic tissues (benign or cancerous) behind, with subse-






























   
   
   





















quent progression may account for the interesting new cohort
of patients. In addition, inadequate PSA testing should be
ruled out, but there remains evidence for hematogenic spread
of prostate cancer cells without involvement of the loco-re-
gional lymphatic drainage in at least 2% of our patients
(4/189). Further studies including descriptive determinations
of biological aggressiveness such as tumor grade, DNA ploidy,
microvascular tumor invasion, and functional molecular mark-
ers of tumor angiogenesis, tumor adhesion, and drug resis-
tance factors [12] are required to thoroughly investigate the
patterns of failure after putatively curative radical prostatec-
tomy. 
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